Anti-Coagulants - Poland

Poland

In Poland, the revenue in the Anti-Coagulants market is estimated to reach US$103.20m in 2024.
It is expected to display an annual growth rate (CAGR 2024-2029) of 7.24%, leading to a market volume of US$146.40m by 2029.
When compared globally, United States is projected to generate the highest revenue with US$16,740.00m in 2024.
Poland is experiencing a growing demand for oral anti-coagulants due to increased awareness and education about cardiovascular health.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

Anti-Coagulants are a type of medication that helps prevent blood clots. In Poland, the Anti-Coagulants market has been experiencing some interesting trends and developments.

Customer preferences: Patients in Poland are increasingly becoming aware of the importance of preventing blood clots. This is leading to an increase in demand for Anti-Coagulants medication. Additionally, the aging population in Poland is also a contributing factor to the growth of the Anti-Coagulants market, as older people are more prone to developing blood clots.

Trends in the market: The Anti-Coagulants market in Poland is experiencing a shift from traditional Anti-Coagulants to newer, more advanced drugs. This is because the newer drugs have fewer side effects and require less monitoring. As a result, they are becoming more popular among patients and healthcare professionals. Additionally, there is a growing trend towards the use of oral Anti-Coagulants, as they are more convenient for patients to take than injectable Anti-Coagulants.

Local special circumstances: In Poland, there is a shortage of doctors, which is leading to longer waiting times for patients. This is particularly problematic for patients who require regular monitoring while taking Anti-Coagulants medication. To address this issue, there is a growing trend towards the use of telemedicine, which allows patients to communicate with their doctors remotely. This is more convenient for patients and can help to reduce waiting times.

Underlying macroeconomic factors: The Polish government has been investing heavily in healthcare in recent years. This has led to an increase in the availability of healthcare services, including Anti-Coagulants medication. Additionally, the Polish economy has been growing steadily, which has led to an increase in disposable income. This has made it easier for patients to afford Anti-Coagulants medication, which has contributed to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.